Sigyn Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SIGY research report →
About the company
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders.
- CEO
- James A. Joyce
- IPO
- 2021
- Employees
- 4
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $72.24K
- P/E
- -0.03
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -1.76
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 49.66%
- ROIC
- 45.18%
- Revenue
- $0 · 0.00%
- Net Income
- $-3,340,212 · 19.43%
- EPS
- $-2.51 · 33.42%
- Op Income
- $-2,519,242
- FCF YoY
- 36.93%
- 52W High
- $5.00
- 52W Low
- $0.01
- 50D MA
- $0.04
- 200D MA
- $1.00
- Beta
- -0.07
- Avg Volume
- 43.86K
Get TickerSpark's AI analysis on SIGY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SIGY coverage
Recent articles, reports, and earnings notes.
No research on SIGY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SIGY report →Similar companies
Peers in the same neighborhood.